Neramexane clinical trials
Includes 7 studies of Neramexane mesylate.
How each study uses neramexane is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Neramexane
- 9
Studies by the year they started
16 studies that test it; most in 2009 (9)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2008 | 4 |
| 2009 | 9 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 0
Studies
Open first, then newest update. How each study uses neramexane is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective TinnitusCompletedPhase 3Merz Pharmaceuticals GmbHNCT00739635Written as Neramexane mesylate
- Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective TinnitusCompletedPhase 3Merz Pharmaceuticals GmbHNCT00955799Written as Neramexane mesylate
- Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective TinnitusTerminatedPhase 3Merz Pharmaceuticals GmbHNCT00827008Written as Neramexane mesylate
- The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's DiseaseCompletedPhase 3Forest LaboratoriesNCT00090116Written as Neramexane
- Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female SubjectsCompletedPhase 1Merz Pharmaceuticals GmbHNCT00915174Written as Neramexane
- Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese SubjectsCompletedPhase 1Merz Pharmaceuticals GmbHNCT00983099Written as Neramexane
- Neramexane for TinnitusCompletedPhase 2Merz Pharmaceuticals GmbHNCT00405886Written as Neramexane
- Evaluation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration): Electrocardiogram (ECG) Study in Healthy Adult SubjectsCompletedPhase 1Merz Pharmaceuticals GmbHNCT00978614Written as Neramexane
- Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane MesylateCompletedPhase 1Merz Pharmaceuticals GmbHNCT00955760Written as Neramexane
- A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male SubjectsCompletedPhase 1Merz Pharmaceuticals GmbHNCT01109680Written as Neramexane
- Open, Single Center, Three Periods, Fixed Sequence Design Study on the Effects of Clopidogrel Co-administration on the Pharmacokinetics of NeramexaneCompletedPhase 1Merz Pharmaceuticals GmbHNCT00936026Written as Neramexane
- Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Study With and Without Application of a Urinary pH Acidification RegimenCompletedPhase 1Merz Pharmaceuticals GmbHNCT00972127Written as Neramexane
- Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective TinnitusCompletedPhase 3Merz Pharmaceuticals GmbHNCT00772980Written as Neramexane mesylate
- Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired NystagmusTerminatedPhase 2Merz Pharmaceuticals GmbHNCT00799942Written as Neramexane mesylate
- Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy VolunteersCompletedPhase 1Merz Pharmaceuticals GmbHNCT00712283Written as Neramexane mesylate
- Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired NystagmusCompletedPhase 2Merz Pharmaceuticals GmbHNCT00661440Written as Neramexane mesylate
Codes
What other systems call neramexane · ClinicalTrials.gg INT004093
- MeSH (NLM) C114144neramexaneOne source NLM
- UNII (FDA) 856DX0KJ84NERAMEXANEConfirmed FDA, NLM, Wikidata
- Wikidata Q6995889neramexaneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76781NeramexaneOne source FDA
- DrugBank DB04926One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C114144 | neramexane | One source NLM |
| UNII (FDA) | 856DX0KJ84 | NERAMEXANE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6995889 | neramexane | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76781 | Neramexane | One source FDA |
| DrugBank | DB04926 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.